Tier 2 — strong

Quercetins efficacy on bone and inflammatory markers, body composition, and physical function in postmenopausal women

Alyssa R Bailly, Garrett M Hester, Michaela G Alesi, Robert J Buresh, Yuri Feito, Christine M Mermier, Jeremy B Ducharme, Trisha A VanDusseldorp
Journal of bone and mineral metabolism 2025 43(3):304-314

Bibliography

PubMed
PMID 40053115
DOI
10.1007/s00774-025-01592-0
Funding
Indexed grant support: ES0765 — Kennesaw State University Department of Exercise Science Research Enhancement Grant Program. The indexed list may not contain the complete funding declaration.
Competing interests
Reported disclosure: Declarations. Conflict of interests: The authors declare that they have no known competing financial interests or personal relationships that could influence the work reported in this paper. Moreover, the authors declare that the article is original, is not under consideration for publication elsewhere nor has this been previously published.

Study snapshot

DesignRandomized double-blind placebo-controlled trial
ModelHuman intervention research
Sample33 postmenopausal women
InterventionQuercetin 500 mg/day versus methylcellulose placebo
Duration90 days
EndpointsInflammatory measures; Bone or cartilage measures

What the study showed, in plain terms

Published in 2025, this source examined cardiovascular and metabolic health. Design: Randomized double-blind placebo-controlled trial. Sample/model: 33 postmenopausal women. The exposure or intervention was Quercetin 500 mg/day versus methylcellulose placebo. Follow-up or treatment period: 90 days.

Bone-formation and resorption markers increased, while IL-6 and TNF-alpha decreased. Body composition, physical function and CRP did not improve.

Increased bone resorption makes a bone-protection interpretation uncertain. Fracture prevention was not established.

Continue with Quercetin Data Center

For topic-level interpretation, read Quercetin for Weight Loss, Blood Sugar and Fatty Liver: Human Evidence. This is a related guide; the citation panel separately identifies articles that directly cite this paper.

Key findings

  • Bone-formation and resorption markers increased, while IL-6 and TNF-alpha decreased.
  • Body composition, physical function and CRP did not improve.
  • The recorded outcome domains were Inflammatory measures; Bone or cartilage measures.
  • The result applies to the tested exposure: Quercetin 500 mg/day versus methylcellulose placebo; 90 days.

What this study can and cannot tell us

  • Increased bone resorption makes a bone-protection interpretation uncertain. Fracture prevention was not established.
  • An individual controlled trial must be interpreted alongside its comparator, sample size, endpoint selection and independent replication. It does not validate a different commercial formulation or a general longevity claim.
  • Source basis: Source check: PubMed abstract and indexed metadata; full methods were not independently confirmed for this entry. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 2
Quercetin Reduces Vascular Senescence and Inflammation in Symptomatic Male but Not Female Coronary Artery Disease Patients
Pauline Mury et al. · Aging cell · 2025
Tier 2
Impact of quercetin in patients with myocardial infarction. A multicenter, randomized, and open-label pilot study
Sergey Kozhukhov et al. · Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese · 2024
Tier 2
Isoquercetin for thromboinflammation in sickle cell disease: a randomized double-blind placebo-controlled trial
Maria A Lizarralde-Iragorri et al. · Blood advances · 2024

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology